The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
there was no difference in PFS between anti-PD1 antibody therapy versus a ipilimumab/nivolumab combination, in the PDL-1 positive population. The study was not powered to distinguish between the ef fi cacy of nivolumab and the ipilimumab/nivolumab combo. The fi nal clinical implications of this study, including the question about the superiority of combined anti-PD1/CTLA-4 therapy versus sequential anti-PD1/CTLA-4 therapy, remain open until the survival data are mature [41].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatologist-level classification of skin cancer with deep neural networks
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017) · Nature · doi:10.1038/nature21056 · Cited by 14,362
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“UV irradiation is associated with a distinct DNA damage signature and a high rate of mutations per megabase (Mb) [4].”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 3×
“Based on very recent randomised trial results, comparing anti-PD1 antibody therapies to ipilimumab, anti-PD1 antibody therapy is the preferred first-line treatment of patients with BRAF-wt disease [42].”
BackgroundMethodInfluentialNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 5×
“73 favouring the combination in patient with LDH >2 x upper limit of normal (ULN) [63, 67], though evidence for the latter is weaker [III, B].”
BackgroundInfluentialSelf-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationFinal Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · cited 1×
“Good references exist for immunotherapies [89] as well as for MAPK inhibitors [90].”
BackgroundGershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citationAdjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationFinal Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310460 · Cited by 1,484
Whole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A.-M., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,461
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Self-citationHodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · cited 1×
“These numerical differences are maintained in the 4-year survival update [65].”
BackgroundLong, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Diagnostic accuracy of dermoscopy
Kittler, H., Pehamberger, H., Wolff, K., & Binder, M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00679-4 · Cited by 1,349
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,321
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citationEggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Self-citationDummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Self-citationAscierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Self-citationLong, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 987
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Reduced melanoma after regular sunscreen use: randomized trial follow-up
Green, A. C., Williams, G. M., Logan, V., & Strutton, G. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7078 · Cited by 799
Davies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640 · cited 1×
“There are early signals from a phase II clinical trial that patients with metastatic melanomas, carrying NRAS mutation, may benefit from MEK kinase-inhibitor therapy [40].”
BackgroundSelf-citationDykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Self-citationDummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30497-2 · Cited by 588
Self-citationTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · cited 1×
“4 the loci of the other known minor BRAF mutations (Class II and Class III BRAF mutant) to confirm WT status and testing for NRAS and c-kit mutations are recommended [II, C][14].”
BackgroundMocellin, S., Pasquali, S., Rossi, C. R., & Nitti, D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq009 · Cited by 527
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8023 · Cited by 516
Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30231-0 · Cited by 509
Self-citationDummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30180-8 · Cited by 499
Self-citationAmerican Society of Clinical Oncology educational book
Perry, M. C. (2003) · Medical Entomology and Zoology · Cited by 471
Grob, J. J., & Bonerandi, J. J. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.1.103-a · Cited by 331
Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17951-3 · Cited by 292
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P., McArthur, G. A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.028 · Cited by 287
Self-citationEggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 285
Self-citationWhiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 273
Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01219 · Cited by 256
Self-citationHenderson, M. A., Burmeister, B. H., Ainslie, J., Fisher, R., Di Iulio, J., Smithers, B. M., Hong, A., Shannon, K., Scolyer, R. A., Carruthers, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00187-4 · Cited by 228
Salerni, G., Carrera, C., Lovatto, L., Puig-Butille, J. A., Badenas, C., Plana, E., Puig, S., & Malvehy, J. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.04.008 · Cited by 228
Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30106-2 · Cited by 216
Self-citationvan der Ploeg, A. P. T., van Akkooi, A. C. J., Rutkowski, P., Nowecki, Z. I., Michej, W., Mitra, A., Newton-Bishop, J. A., Cook, M., van der Ploeg, I. M. C., Nieweg, O. E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6760 · Cited by 208
Self-citationZimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 190
Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A., Berking, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx079 · Cited by 177
Self-citationIves, N. J., Suciu, S., Eggermont, A. M. M., Kirkwood, J., Lorigan, P., Markovic, S. N., Garbe, C., Wheatley, K., Bufalino, R., Cameron, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.006 · Cited by 174
Schadendorf, D., Long, G. V., Stroiakovski, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion-Sileni, V., Schachter, J., Garbe, C., Dutriaux, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.033 · Cited by 173
Beaver, J. A., Hazarika, M., Mulkey, F., Mushti, S., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 171
Sosman, J. A., Moon, J., Tuthill, R. J., Warneke, J. A., Vetto, J. T., Redman, B. G., Liu, P. Y., Unger, J. M., Flaherty, L. E., & Sondak, V. K. (2011) · Cancer · doi:10.1002/cncr.26111 · Cited by 168
van der Ploeg, A. P. T., van Akkooi, A. C. J., Haydu, L. E., Scolyer, R. A., Murali, R., Verhoef, C. K., Thompson, J. F., & Eggermont, A. M. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.023 · Cited by 147
Hollestein, L. M., van den Akker, S. A. W., Nijsten, T. E. C., Karim‐Kos, H. E., Coebergh, J. W. W., & de Vries, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr128 · Cited by 135
Prognostic false-positivity of the sentinel node in melanoma
Thomas, J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1014 · Cited by 133
Minniti, G. C., Anzellini, D., Reverberi, C., Cappellini, G. C. A., Marchetti, L., Bianciardi, F., Bozzao, A., Osti, M. F., Gentile, P. C., & Esposito, V. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0588-y · Cited by 123
DAUD, A. I., & Tsai, K. K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 97
Valpione, S., Carlino, M. S., Mangana, J., Mooradian, M. J., McArthur, G. A., Schadendorf, D., Hauschild, A., Menzies, A. M., Arance, A. M., Ascierto, P. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.007 · Cited by 97
Self-citationBastiaannet, E., Wobbes, T., Hoekstra, O. S., van der Jagt, E. J., Brouwers, A. H., Koelemij, R., de Klerk, J. M. H., Oyen, W. J. G., Meijer, S., & Hoekstra, H. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1822 · Cited by 94
Robert, C., Flaherty, K. T., Nathan, P., Hersey, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Mohr, P., Hassel, J. C., Rutkowski, P. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.015 · Cited by 88
Self-citationUpdated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
Dummer, R., Guggenheim, M., Arnold, A., Braun, R. P., & von Moos, R. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13320 · Cited by 87
Self-citationGaudy‐Marqueste, C., Dussouil, A.-S., Carron, R., Troin, L., Malissen, N., Loundou, A., Monestier, S., Mallet, S., Richard, M. A., Régis, J. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.017 · Cited by 83
Bono, A., Tolomio, E., Trincone, S., Bartoli, C., Tomatis, S., Carbone, A., & Santinami, M. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07396.x · Cited by 78 · cited 1×
“Today, many primary melanomas have a diameter of <5 mm [5].”
BackgroundWeber, J. S., Mandalà, M., Vecchio, M. D., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion‐Sileni, V., Márquez‐Rodas, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9502 · Cited by 76
Self-citationVerver, D., Klaveren, D. V., van Akkooi, A. C. J., Rutkowski, P. L., Powell, B. W. E. M., Robert, C., Testori, A., van Leeuwen, B. L., van der Veldt, A. A. M., Keilholz, U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.022 · Cited by 67
Self-citationSchadendorf, D., Amonkar, M. M., Milhem, M. M., Grotzinger, K. R., Демидов, Л. В., Rutkowski, P. L., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt580 · Cited by 58
Self-citationMiura, J. T., Kroon, H. M., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M., Farley, C. R., Kim, Y., Naqvi, S. M. H., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07288-w · Cited by 48
Advances in the systemic treatment of melanoma brain metastases
Oliva, I. C. G., Schvartsman, G., & Tawbi, H. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy185 · Cited by 41
Latimer, N. R., Bell, H., Abrams, K. R., Amonkar, M. M., & Casey, M. (2016) · Cancer Medicine · doi:10.1002/cam4.643 · Cited by 32
Critical aspects to achieve a high-quality melanoma clinic
Dummer, R., Ramelyte, E., Levesque, M. P., Goldinger, S. M., & Braun, R. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000357 · Cited by 6
Self-citation
Cited by
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Rohaan, M. W., Borch, T. H., van den Berg, J. H., Met, Ö., Kessels, R., Geukes Foppen, M. H., Stoltenborg Granhøj, J., Nuijen, B., Nijenhuis, C., Jedema, I., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210233 · Cited by 568
Self-citationTyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005493 · Cited by 408
Self-citation
Metadata
- Authors
- Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 30
- Issue
- 12
- Pages
- 1884-1901
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4256631179
- Cited by
- 617
- References
- 78
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.